+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07142356

Randomized Study Comparing Modified Release RTN-001 to Placebo in Adults With Uncontrolled Hypertension

Led by Retension Pharmaceuticals. Inc. · Updated on 2026-11-04

280

Participants Needed

44

Research Sites

13 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are studying the safety and effectiveness of RTN-001, a modified release drug, in adults aged 18 to 75 years with uncontrolled and resistant hypertension, defined as systolic blood pressure SBP of 135 mm Hg or higher and diastolic blood pressure DBP of 80 mm Hg or higher. This Phase 2b trial is randomized, double-blind, and involves multiple centers. The study includes three main periods Screening, Run-in, and Treatment. During the trial, about 280 eligible participants will be randomly assigned equally into four groups to receive one of three doses of RTN-001 15 mg, 30 mg, or 45 mg or a matching placebo. The treatment lasts for 12 weeks. After the treatment period ends, participants will have an off-treatment follow-up visit two weeks later to assess their condition. Participants will be involved in various assessments throughout the study, including blood pressure measurements taken at multiple time points during and after treatment. Researchers will monitor changes in systolic and diastolic blood pressure using office measurements, central blood pressure readings, and ambulatory monitoring. Safety and efficacy will be evaluated through these repeated measures, and adherence to the study drug will be tracked. The total participation includes screening, run-in, treatment, and follow-up visits spanning several months.

CONDITIONS

Brief Title

A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension

Research Team

C

Clinical Information

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here